NGL Fine-Chem Ltd. (IN:NGLFINE)
:NGLFINE
Want to see IN:NGLFINE full AI Analyst Report?
Top Page
NGL Fine-Chem Ltd.
(NGLFINE)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹2,324.00
▲(62.86% Upside)
Action:ReiteratedDate:03/14/26
The score is primarily driven by solid financial growth trends but offset by weaker recent profitability and negative free cash flow. Technicals are mixed with near-term softness despite a broader uptrend. Valuation is a supportive factor due to a moderate P/E and a high dividend yield.
Positive Factors
Multi-year Revenue Growth
Sustained multi-year revenue growth demonstrates expanding commercial traction and market penetration. Durable top-line momentum supports scale economics, allows reinvestment in capacity or product development, and underpins medium-term competitiveness even if margins fluctuate.
Negative Factors
Declining Net Income
Recent declines in net income signal weakening bottom-line performance despite revenue gains. Persistent profit erosion reduces retained earnings, pressures return metrics and dividend capacity, and could restrict reinvestment or margin recovery without structural cost or pricing fixes.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year Revenue Growth
Sustained multi-year revenue growth demonstrates expanding commercial traction and market penetration. Durable top-line momentum supports scale economics, allows reinvestment in capacity or product development, and underpins medium-term competitiveness even if margins fluctuate.
Read all positive factors
NGL Fine-Chem Ltd. (NGLFINE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹13.87B
Dividend Yield0.13%
Average Volume (3M)156.00
Price to Earnings (P/E)13.8
Beta (1Y)0.90
Revenue Growth19.79%
EPS Growth7.56%
CountryIN
Employees682
SectorBasic Materials
Sector Strength58
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)25.40
Shares Outstanding6,178,024
10 Day Avg. Volume192
30 Day Avg. Volume156
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)2.47
Price to Sales (P/S)1.89
P/FCF Ratio-7.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NGL Fine-Chem Ltd. Business Overview & Revenue Model
Company Description
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, ...
How the Company Makes Money
Revenue is generated primarily from the sale of the company’s chemical products to customers (typically B2B). Specific breakdowns of revenue streams by product categories (e.g., intermediates, specialty chemicals, custom synthesis/contract manufac...
NGL Fine-Chem Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.09B | 3.68B | 3.39B | 2.78B | 3.18B | 2.58B |
| Gross Profit | 2.08B | 1.86B | 1.70B | 1.38B | 1.66B | 1.53B |
| EBITDA | 476.13M | 338.69M | 678.69M | 404.87M | 788.78M | 881.27M |
| Net Income | 206.86M | 211.24M | 413.17M | 204.96M | 498.97M | 567.19M |
Balance Sheet | ||||||
| Total Assets | 4.84B | 4.33B | 3.56B | 2.87B | 2.77B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 637.29M | 655.28M | 553.14M | 525.02M | 295.49M | 338.51M |
| Total Debt | 882.03M | 731.53M | 340.04M | 324.99M | 300.01M | 164.48M |
| Total Liabilities | 1.84B | 1.51B | 929.04M | 645.30M | 737.10M | 533.08M |
| Stockholders Equity | 3.00B | 2.82B | 2.63B | 2.23B | 2.03B | 1.54B |
Cash Flow | ||||||
| Free Cash Flow | -82.44M | -949.49M | -80.59M | 38.80M | -425.52M | 101.42M |
| Operating Cash Flow | 167.72M | 358.22M | 204.65M | 352.86M | 138.25M | 273.54M |
| Investing Cash Flow | -143.73M | -345.53M | -268.17M | -270.20M | -142.03M | -245.68M |
| Financing Cash Flow | -10.81M | -10.81M | -10.81M | -10.81M | -10.81M | -10.81M |
NGL Fine-Chem Ltd. Technical Analysis
Positive
1427.00
Price Trends
2232.66
Negative
1818.10
Positive
1599.58
Positive
Market Momentum
26.60
Negative
50.43
Neutral
49.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NGLFINE, the sentiment is Positive. The current price of 1427 is below the 20-day moving average (MA) of 2210.24, below the 50-day MA of 2232.66, and below the 200-day MA of 1599.58, indicating a neutral trend. The MACD of 26.60 indicates Negative momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 49.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NGLFINE.
NGL Fine-Chem Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹83.68B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
70 Outperform | ₹37.89B | 29.96 | ― | 0.13% | 14.96% | 27.42% | |
66 Neutral | ₹13.87B | 13.84 | ― | 0.13% | 19.79% | 7.56% | |
64 Neutral | ₹7.95B | 19.44 | ― | 1.96% | -3.66% | -65.22% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹288.49B | 27.13 | ― | 1.07% | 6.70% | 20.25% |
* Basic Materials Sector Average
IN:NGLFINE
NGL Fine-Chem Ltd.
2,244.70
1,136.30
102.52%
IN:GLAND
Gland Pharma Ltd.
1,751.00
345.34
24.57%
IN:KOPRAN
Kopran Limited
164.70
-21.91
-11.74%
IN:MARKSANS
Marksans Pharma Limited
184.65
-36.92
-16.66%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
404.55
159.79
65.28%
IN:SENORES
Senores Pharmaceuticals Ltd.
898.70
393.30
77.82%
NGL Fine-Chem Ltd. Corporate Events
NGL Fine-Chem Outlook Raised to Stable by Crisil
Mar 13, 2026
NGL Fine-Chem Limited announced that Crisil Ratings has revised the outlook on its long-term bank loan facilities to Stable from Negative, while reaffirming the long-term rating at Crisil BBB+. The short-term rating has been reaffirmed at Crisil A...
NGL Fine-Chem Board Clears Q3 FY26 Results, Appoints New Company Secretary
Feb 3, 2026
NGL Fine-Chem Ltd.’s board has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, along with the limited review report from its statutory auditors, reinforcing regulat...
NGL Fine-Chem Clears Q3 FY26 Results, Appoints New Compliance Head
Feb 3, 2026
NGL Fine-Chem Ltd. announced that its board of directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, which have been reviewed by the statutory auditors in line wi...
NGL Fine-Chem Confirms SEBI-Compliant Dematerialisation of Securities for December Quarter
Jan 3, 2026
NGL Fine-Chem Ltd. has informed the stock exchanges that, based on confirmation from its registrar and transfer agent Purva Sharegistry (India) Pvt. Ltd., all securities received for dematerialisation between October 1, 2025 and December 30, 2025 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.